Whatʼs in the web for family physicians -
gut microbiome and its influence on health
Sio-pan Chan 陳少斌,Wilbert WB Wong 王維斌,Alfred KY Tang 鄧權恩
HK Pract 2021;43:11-12
The gut microbiome is undoubtedly one of the
hottest topics in medicine in the past decade or so.
Potentially this could be a new paradigm shift in the
management of many diseases. The term “microbiome”
is practically used synonymously with “microbiota”.
Actually, “microbiota” refers to all the bacteria, fungi,
viruses and microbes that can be identified by means
of earlier 16s rRNA genes sequencing technique.
“Microbiome”, on the other hand, includes all the
“microbiota” plus any genomes and genetic metabolites
that can be detected by the more advanced techniques
such as shotgun sequencing, next generation sequencing
techniques and mass spectrometry. Therofore,
“microbiome” is probably a more comprehensive and
precise term in describing the gut ecology system.
We acquire our gut microbiome since birth and it
takes about 2 to 3 years to develop into a unique adult
pattern specific to each individual. There are many
factors that can affect the characteristics of one’s gut
microbiome. The more important ones include mode of
delivery (vaginal vs Caesarean Section), genetics, race,
geographic location, diet, aging, drugs and particularly
antibiotics intake. As most of our gut bacteria are
anaerobes and cannot be cultured for study, we are
only beginning to understand the complexity of our gut
microbiome with the advent of metagenomic analysis.
On average, an adult has about 2kg of gut
bacteria, our gut microbiome has at least 100 times
more cells than our whole body. It contains over a few
hundred times more genes than human. On average,
typical gut microbiome contains over 3.3 million
microbial genes compared with 23,000 genes in
human genome. There are enough toxins and harmful
bacteria in our gut to kill us multiple times. Yet our
body's defence against this constant threat relies on a
single cell thick lining of epithelial cells. Behind this
epithelium, we have the largest collection of lymphoid
cells making our gut the biggest immune organ in
the body. Also found in our gut lining, there are over
100 million neurons. This is the largest collection of
neurons outside our brain, this Enteric Nervous System
(ENS) is considered by some as our second brain.
Given such close relationships, it is easy to envisage
that even a slight tipping of this homeostatic balance
could have profound effects on our health.
Interestingly, as early as in the 16th Century the
famous Chinese physician (李時珍) had already used
faecal extract (人中黃) to treat severe diarrhoea. It was
not until 1978, the first successful faecal transplant
(FMT) to treat Clostridium Difficile infection (CDI)
was documented. More recent studies revealed that
the gut microbiome have a much wider influence
in many aspects of our health and potentially can
modify our treatment approach to many medical
conditions. Experiments by transplanting human faecal
materials into laboratory germ free mice demonstrated
microbiome have a significant effect on obesity. The
mice that had received FMT from obese human became
obese mice, while those received transplants from
lean person became lean mice. Furthermore, faecal
transplant from young mouse to an old mouse with
cognitive impairment can improve cognitive function
of the older mouse. Other potential applications of
faecal microbiome may include asthma, autoimmune
conditions, inflammatory bowel diseases, depression,
autism related syndromes, etc. We shall try to explore
this Pandora's Box by looking at the available literature
in the internet.
It should be noted that not all stools are equal,
it is extremely difficult to find a healthy stool donor
or become one. Also there are no definitive superior
route of administration, dose or duration of treatment
for any condition. It is much too early to tell whether
this is going to be a real paradigm shift or just another
medical hype. Up to the present moment, FDA only
approves FMT in treatment of resistant CDI, all other
applications are to be done on clinical trial basis.
Treatment of severe or recurrent clostridium
difficile infection
Randomised clinical trial: faecal microbiota
transplantation by colonoscopy vs. vancomycin
for the treatment of recurrent clostridium
difficile infection (CDI)
https://doi.org/10.1111/apt.13144
The present indication for FMT is for severe
or recurrent CDI. RCT trials revealed an over
90% efficacy compared with <
30% success rate of
conventional treatment with vancomycin. (In 2015 FDA
has issued warning concerning safety of FMT because
of a few cases of post FMT infections). FMT remains to
be the most effective treatment severe or recurrent CDI.
Short Chain Fatty Acids (SCFAs)-Mediated
gut epithelial and immune regulation and its
relevance for inflammatory bowel diseases
https://doi.org/10.3389/fimmu.2019.00277
Production of short chain fatty acids (SCFAs),
SCFAs (acetate, propionate, and butyrate) are essential
for maintaining the integrity of the bowel mucosal
lining. The mucosal lining is the largest component
of the entire immune system. Any deficiencies in
this lining can result in leaky gut syndrome, IBS,
inflammatory bowel diseases etc.
The brain-gut-microbiome axis
https://doi.org/10.1016%2Fj.jcmgh.2018.04.003
Studies have shown bidirectional interactions
within the brain-gut-microbiome axis. Gut microbes
communicate to the central nervous system through at
least three parallel and interacting channels involving
nervous, endocrine, and immune signalling mechanisms.
Alternatively the brain can affect the community
structure and function of the gut microbiome through
the autonomic nervous system, localised gut mobility,
permeability and many other pathways.
The vagus nerve at the interface of the microbiota-gut-
brain axis
https://doi.org/10.3389%2Ffnins.2018.00049
The Vagus nerve is the principal component of the
parasympathetic system. It is bi-directionally connecting
the CNS and ENS (enteric nervous system) and act as a
moderator between the brain and the gut microbiome.
A novel faecal Lachnoclostridium marker for
the non-invasive diagnosis of colorectal adenoma
and cancer
https://doi.org/10.1136/gutjnl-2019-318532
Colorectal cancer - the gut microbiome has an
important role in the carcinogenesis of CRC. New
studies had identified specific markers for colorectal
polyps and colorectal cancers. It opened up a new way
of screening for colorectal polys and cancers without
going through colonoscopy.
Fecal Microbiota Transplantation relieves
gastrointestinal and autism symptoms by
improving the gut microbiota in an open-label
study
https://doi.org/10.3389/fcimb.2021.759435
The authors of this recent trial in China proved
that FMT was well tolerated and effective in improving
gastrointestinal symptoms and autism-like behaviours in
children with Autism Spectrum Disorder (ASD). FMT
seemed to induce the production of a microbiota that
was significantly different from the pre-FMT microbiota
and much more similar to those of the healthy donor
and typically developing children.
Effect of fecal microbiota transplant on symptoms
of psychiatric disorders: a systematic review
https://doi.org/10.1186/s12888-020-02654-5
Associations between gut microbiome and
depression have been observed in recent years. The
Gut-Brain-Axis is a bidirectional signalling pathway
between the gastrointestinal (GI) tract and the brain.
The gut microbes and their metabolites are thought to
be the modulators of this connection. They have far
reaching effects on the immune system, central and
autonomic nervous systems, and GI functioning. These
interactions have also been linked to various psychiatric
illnesses such as depression, anxiety, substance abuse,
autism spectrum and eating disorders. It is hypothesised
that techniques aimed at strengthening and repopulating
the gut microbiome, such as FMT may be useful in
the prevention and treatment of psychiatric illnesses.
Further FMT studies in psychiatric illnesses could be
worth pursuing, crucial in determining the potential of
FMT in psychiatric illnesses.
Systematic review with meta-analysis:
encapsulated faecal microbiota transplantation –
evidence for clinical efficacy
https://doi.org/10.1177%2F17562848211041004
Faecal microbiome transplantation can be
performed in different ways such as through endoscopy,
enemas or capsules. The transfer through capsules is
preferred by the patients and has the advantages that
it can be administered long-term and can be delivered
to the patients in their home. Treatment with capsules
is safe when guidelines for screening donors and
testing faecal material are followed. The treatment
is highly effective in the treatment of recurrent C.
difficile infection, often caused by repeated antibiotic
treatments. Faecal microbiome transplantation delivered
through capsules is as effective as treatment delivered
through other routes in the treatment of C. difficile
infection. There are promising results in the treatment
of other diseases such as liver disease, inflammatory
bowel disease and the treatment of multi-drug resistant
bacteria.
Influence of diet on the gut microbiome and
implications for human health
https://doi.org/10.1186%2Fs12967-017-1175-y
Diet plays a significant role in shaping the
microbiome. This review evaluated systematically the
current data regarding the effects of several common
dietary components on intestinal microbiome. The
conclusion from this paper suggests plant proteins
increase SCFA and reduce inflammatory while animal
proteins are pro-inflammatory by reducing SCFA. A
low fat diet leads to increased faecal abundance of
Bifidobacterium with concomitant reductions in fasting
glucose and total cholesterol, compared to baseline.
Diet rich in high saturated fat increases the relative
proportion of Faecalibacterium prausnitzii. Nondigestible
carbohydrates such as fibre travel to the large
intestine where they undergo fermentation by resident
microorganisms. High intake of these carbohydrates in
49 obese subjects resulted in an increase in microbiota
gene richness. Hence, dietary fibres are the most
essential components in promoting microbiota health.
Therapeutic mechanisms of traditional Chinese
medicine to improve metabolic diseases via the
gut microbiota
https://doi.org/10.1016/j.biopha.2020.110857
Metabolic diseases such as obesity, type 2 diabetes
mellitus, and hyperlipidaemia are associated with the
dysfunction of gut microbiota. Traditional Chinese
medicines (TCMs) have considerable effects in the
treatment of metabolic disorders by regulating the gut
microbiota. However, the underlying mechanisms are
still unclear. Studies have found that hypoglycaemic
drugs like metformin or acarbose can treat metabolic
diseases by altering gut microbiota. Studies have also
shown that TCMs significantly affect glucose and
lipid metabolism by modulating the gut microbiota,
particularly mucin-degrading bacteria, bacteria with
anti-inflammatory properties, lipopolysaccharide-and
short-chain-fatty-acid-producing bacteria, and
bacteria with bile-salt hydrolase activity. In this review,
scientists explored potential mechanisms by which
TCMs improved metabolic disorders via regulating gut
microbiota composition and functional structure.
Gut microbiota: a new angle for traditional herbal
medicine research
https://pubs.rsc.org/en/content/articlelanding/2019/ra/
c9ra01838g
Traditional Herbal Medicine (THM) has been
used for thousands of years. However, the effective
ingredients in the herbal formulations and their
underlying mechanisms of actions are still unknown.
In this review, scientists had investigated the studies
available that focused on the efficacy, active ingredients
and bioavailability of THM, and the role of gut
microbiota in THM-mediated treatment of diseases.
During growth and reproduction, gut microbiota
produces several enzymes which can degrade Traditional
Herbal Medicine components. The active components
are transformed into new active metabolites by the
action of specific microbial enzymes, which then exert
different biological effects.
For example, Saponins have antipyretic, sedative
and anti-cancer effects, and are commonly present
in ginseng, Panax notoginseng and Bupleurum.
Ginsenosides are the main active constituents of P.
ginseng, and are metabolised to compound K (20-O-(b-d-glucopyranosyl)-20(S)-protopanaxadiol) by gut
microbiota before absorption into the circulation.
Compound K has hepato-protective, anti-cancer, anti-wrinkling,
and anti-aging properties, and is more potent
than the parental ginsenosides. More examples are
included in the article and will give readers a better
insight into the mechanism of the Traditional Herbal
Medicines.
Sio-pan Chan, MBBS (HK), DFM (HKCU), FHKFP, FHKAM (Family Medicine)
Family Physician in private practice
Wilbert WB Wong,FRACGP, FHKCFP, Dip Ger MedRCPS (Glasg), PgDipPD (Cardiff)
Family Physician in private practice
Alfred KY Tang,MBBS (HK), MFM (Monash)
Family Physician in private practice
Correspondence to: Dr Sio-pan Chan, SureCare Medical Centre (CWB), Room 1116-7,
11/F, East Point Centre, 555 Hennessy Road, Causeway Bay,
Hong Kong SAR.
E-mail: siopanc@gmail.com
|